Metabolic dysfunction-associated fatty liver disease, most commonly known as nonalcoholic fatty liver disease (NAFLD), has a prevalence of about 30% in the general population and about 80% in people with obesity. It is characterized by steatosis and metabolic dysfunction, with inflammation and fibrogenesis.
Boehringer Ingelheim GmbH’s start to the new year includes two fresh deals across two continents. BI struck one deal with Kunshan, China-based Suzhou Ribo Life Science Co. Ltd. and its Mölndal, Sweden-based subsidiary, Ribocure Pharmaceuticals AB, to develop small interfering RNA (siRNA) treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis. It struck a second deal with San Francisco-based 3T Biosciences Inc. to develop cancer immunotherapies, which builds on an earlier collaboration formed last year. Combined, the two deals are worth more than $2.5 billion.
Suzhou Ribo Life Science Co. Ltd. and Ribocure AB have entered into a collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
Recent studies have identified 70 oxygenized phosphatidylcholine (PC)-containing epoxy and hydroperoxide groups that are generated in the early phase of acetaminophen (APAP)-induced acute liver injury. In a new study, researchers from the University of Tokyo focused on arachidonate PC and assessed the role of liver-specific LPCAT3 (lysophospholipid acyltransferase 3) on APAP-induced acute liver injury in mice.
Equillium Inc. has announced that it intends to advance EQ-302, a preclinical orally delivered multi-cytokine inhibitor of IL-15 and IL-21, in place of further clinical development of EQ-102.
The FDA has awarded orphan drug designation to Ocelot Bio Inc.'s lead candidate OCE-205 for the treatment of ascites due to all etiologies except cancer. Ocelot Bio plans to initiate clinical studies of OCE-205 in refractory ascites next year.
Astrazeneca AB has disclosed 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic steatosis, liver inflammation, hepatitis C virus infection and liver cancer.
X-Chem Inc. has synthesized 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH).
Researchers from Mitsubishi Tanabe Pharma Corp. and affiliated organizations have described the discovery and preclinical evaluation of a novel adiponectin receptor (AdipoR)-activating monoclonal antibody, named AdipoRaMab, being developed for the treatment of type 2 diabetes and nonalcoholic steatohepatitis (NASH).
RSS
